EP2069376A4 - Herbeiführung zellulärer immunreaktionen auf das influenzavirus mithilfe von peptid- und nukleinsäure-zusammensetzungen - Google Patents

Herbeiführung zellulärer immunreaktionen auf das influenzavirus mithilfe von peptid- und nukleinsäure-zusammensetzungen

Info

Publication number
EP2069376A4
EP2069376A4 EP07861332.0A EP07861332A EP2069376A4 EP 2069376 A4 EP2069376 A4 EP 2069376A4 EP 07861332 A EP07861332 A EP 07861332A EP 2069376 A4 EP2069376 A4 EP 2069376A4
Authority
EP
European Patent Office
Prior art keywords
peptide
nucleic acid
influenza virus
immune responses
cellular immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07861332.0A
Other languages
English (en)
French (fr)
Other versions
EP2069376A2 (de
Inventor
Jeffery L Alexander
Scott F Southwood
Pamuk A Bisel
Mark J Newman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmexa Inc
Original Assignee
Pharmexa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa Inc filed Critical Pharmexa Inc
Publication of EP2069376A2 publication Critical patent/EP2069376A2/de
Publication of EP2069376A4 publication Critical patent/EP2069376A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP07861332.0A 2006-07-21 2007-07-23 Herbeiführung zellulärer immunreaktionen auf das influenzavirus mithilfe von peptid- und nukleinsäure-zusammensetzungen Withdrawn EP2069376A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83211206P 2006-07-21 2006-07-21
PCT/US2007/016529 WO2008039267A2 (en) 2006-07-21 2007-07-23 Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Publications (2)

Publication Number Publication Date
EP2069376A2 EP2069376A2 (de) 2009-06-17
EP2069376A4 true EP2069376A4 (de) 2013-10-16

Family

ID=39230737

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07861332.0A Withdrawn EP2069376A4 (de) 2006-07-21 2007-07-23 Herbeiführung zellulärer immunreaktionen auf das influenzavirus mithilfe von peptid- und nukleinsäure-zusammensetzungen

Country Status (4)

Country Link
EP (1) EP2069376A4 (de)
AU (1) AU2007300663A1 (de)
CA (1) CA2658559A1 (de)
WO (1) WO2008039267A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009053535A2 (en) * 2007-10-26 2009-04-30 Glykos Finland Oy Peptide vaccine for influenza virus
EA017957B1 (ru) 2007-06-25 2013-04-30 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Композиции и способы, ингибирующие грипп
WO2009016639A2 (en) 2007-08-02 2009-02-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
FI20080333A0 (fi) * 2008-05-02 2008-05-02 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
AU2008364200B2 (en) * 2008-11-19 2016-01-28 Laboratorio Avi-Mex, S.A. De C.V. Recombinant inactivated viral vector vaccine
US8282938B2 (en) 2008-11-28 2012-10-09 National Institute Of Infectious Diseases Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
WO2010088393A2 (en) * 2009-01-28 2010-08-05 Antigen Express, Inc. Li-kay hybrid peptides that modulate the immune response to influenza
CN101792745B (zh) * 2009-02-04 2014-09-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa氨基端多肽的表达纯化及pa氨基端多肽的晶体结构
CN101565455B (zh) * 2009-05-25 2012-03-14 中国科学院微生物研究所 禽流感h5n1病毒的ctl表位多肽及其应用
WO2010139047A1 (en) * 2009-06-01 2010-12-09 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
EP2459716B1 (de) 2009-07-31 2016-08-17 Paxvax, Inc. Adenovirus-vektoren
JP2013506682A (ja) * 2009-09-30 2013-02-28 セント ルイス ユニバーシティ 異種亜型インフルエンザｔ細胞応答を誘発するためのペプチド
CN102153621B (zh) * 2010-02-12 2014-07-02 广东省疾病预防控制中心 新型甲型h1n1流感na蛋白b细胞表位及其应用
AU2010346373A1 (en) * 2010-02-19 2012-08-02 Universite De Liege A polynucleotide for use in treatment of influenza A virus induced diseases, encoding modified Mx protein, said modified Mx protein, and a transgenic animal expressing gene encoding modified Mx protein
WO2011138032A2 (en) * 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
EP2794630A4 (de) 2011-12-22 2015-04-01 Alios Biopharma Inc Substituierte phosphorthioat-nukleotidanaloga
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
AU2014204826A1 (en) * 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
CN103333224B (zh) * 2013-05-10 2015-03-25 中国农业科学院哈尔滨兽医研究所 禽流感病毒ns1蛋白b细胞抗原表位多肽及其应用
JP6525214B2 (ja) * 2014-06-03 2019-06-05 国立研究開発法人農業・食品産業技術総合研究機構 抗体またはその可変領域を含む抗体断片、抗原ポリペプチド、およびその利用
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
CN106589105B (zh) * 2017-01-23 2020-09-15 中国医科大学 Hla-a2限制性ecm1特异性的ctl表位肽及其应用
US11517617B2 (en) 2017-09-08 2022-12-06 The University Of Melbourne Methods and compositions for preventing influenza infection
US12239699B2 (en) 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020086927A1 (en) 2018-10-26 2020-04-30 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses
US20230248817A1 (en) * 2020-06-19 2023-08-10 Intervet Inc. Swine influenza a virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding distinct neuraminidase antigens of the virus
WO2021255221A1 (en) * 2020-06-19 2021-12-23 Intervet International B.V. Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages
US20230270838A1 (en) * 2020-08-02 2023-08-31 Richard Ascione Vaccine compositions for influenza viruses and methods of use
WO2022046895A2 (en) * 2020-08-25 2022-03-03 Genentech, Inc. Assays and reagents for characterization of mhci peptide binding
CN116410271B (zh) * 2023-03-13 2024-07-19 华南农业大学 H5n1亚型aiv mhc b1限制性t细胞表位肽及其应用
CN120004989B (zh) * 2025-01-16 2025-12-05 华南农业大学 H5n1亚型aiv mhc b4限制性t细胞表位肽及其筛选方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060153871A1 (en) * 2005-01-11 2006-07-13 Olsen Christopher W H3 equine influenza A virus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060153871A1 (en) * 2005-01-11 2006-07-13 Olsen Christopher W H3 equine influenza A virus

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALEXANDER J ET AL: "Identification of broad binding class I HLA supertype epitopes to provide universal coverage of influenza A virus", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 71, no. 5, 1 May 2010 (2010-05-01), pages 468 - 474, XP027006096, ISSN: 0198-8859, [retrieved on 20100310] *
EBERL GERARD ET AL: "Immunodominance of cytotoxic T lymphocyte epitopes co-injected in vivo and modulation by interleukin-12", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 26, no. 11, 1996, pages 2709 - 2716, XP055244817, ISSN: 0014-2980 *
EPSTEIN SUZANNE L ET AL: "DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice", EMERGING INFECTIOUS DISEASES, vol. 8, no. 8, August 2002 (2002-08-01), pages 796 - 801, XP002712185, ISSN: 1080-6040 *
FRUCI D ET AL: "Anchor residue motifs of HLA class I-binding peptides analysed by the direct binding of synthetic peptides to HLA class I alpha chains", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 36, no. 1, 1 January 1993 (1993-01-01), pages 67, XP023851425, ISSN: 0198-8859, [retrieved on 19930101], DOI: 10.1016/0198-8859(93)90104-9 *
GIANFRANI C ET AL: "Human memory CTL response specific for influenza A virus is broad and multispecific", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 61, no. 5, 1 May 2000 (2000-05-01), pages 438 - 452, XP002492007, ISSN: 0198-8859, DOI: 10.1016/S0198-8859(00)00105-1 *
GUERCIO DEL M-F ET AL: "BINDING OF A PEPTIDE ANTIGEN TO MULTIPLE HLA ALLELES ALLOWS DEFINITION OF AN A2-LIKE SUPERTYPE", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 154, 1 January 1995 (1995-01-01), pages 685 - 693, XP002055570, ISSN: 0022-1767 *
ISHIOKA G Y ET AL: "UTILIZATION OF MHC CLASS I TRANSGENIC MICE FOR DEVELOPMENT OF MINIGENE DNA VACCINES ENCODING MULTIPLE HLA-RESTRICTED CTL EPITOPES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 162, no. 7, 1 April 1999 (1999-04-01), pages 3915 - 3925, XP000872894, ISSN: 0022-1767 *
KUBO R T ET AL: "DEFINITION OF SPECIFIC PEPTIDE MOTIFS FOR FOUR MAJOR HLA-A ALLELES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 152, no. 8, 1 January 1994 (1994-01-01), pages 3913 - 3924, XP002936662, ISSN: 0022-1767 *
LIVINGSTON B D ET AL: "Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines", VACCINE, ELSEVIER LTD, GB, vol. 19, no. 32, 14 September 2001 (2001-09-14), pages 4652 - 4660, XP004303157, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(01)00233-X *
SIDNEY J ET AL: "SPECIFICITY AND DEGENERACY IN PEPTIDE BINDING TO HLA-B7-LIKE CLASS I MOLECULES", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 157, no. 8, 15 October 1996 (1996-10-15), pages 3480 - 3490, XP002055572, ISSN: 0022-1767 *
THRELKELD S C ET AL: "Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 AUG 1997, vol. 159, no. 4, 15 August 1997 (1997-08-15), pages 1648 - 1657, XP002712184, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP2069376A2 (de) 2009-06-17
AU2007300663A1 (en) 2008-04-03
CA2658559A1 (en) 2008-04-03
WO2008039267A2 (en) 2008-04-03
WO2008039267A3 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
EP2066339A4 (de) Zusammensetzungen und verfahren zur verstärkung von immunreaktionen
PL3178490T3 (pl) Kompozycje białka f rsv i sposoby ich wytwarzania
PL1976559T6 (pl) Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
EP2442829A4 (de) Strukturierte viralpeptidzusammensetzungen und verwendungsverfahren dafür
PL3211077T3 (pl) Sposoby oczyszczania rekombinowanego adamts13 i innych białek oraz ich kompozycje
IL222762A0 (en) Neutralizing antibodies to influenza viruses
BRPI1012811A2 (pt) vacinas contra o vírus herpes simplex tipo 2: composições e métodos para obtenção de uma resposta imune
IL215451A (en) Antigenic structures that include the antigenic peptide of the tao protein and their pharmacological preparations
ZA200802892B (en) Vaccines and methods to treat canine influenza
IL209136A0 (en) Compositions of peptides and processes of preparation thereof
PT2193142E (pt) Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
IL215955A (en) Uracil Spiruoxetan Nucleosides, Preparations Containing Them and Uses as HCV Inhibitors
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
EP2091960A4 (de) Peptidimpfstoff gegen das grippevirus
IL217709A (en) Add recombinant viruses, preparations and vaccines containing them and their uses to encourage cellular and humoral immune response
IL212545A (en) Isolated antibodies that bind to 3tlr and their pharmaceutical preparations
BRPI1006863A2 (pt) composições de vacina e plasmodium purificado
IL213189A0 (en) Recombinant avian influenza vaccine and uses thereof
IL209027A0 (en) Vaccine compositions and uses thereof
PL2658570T3 (pl) Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b
ZA200809056B (en) Influenza virus vaccine
FI20080333A0 (fi) Influenssaviruksen nukleiinihappoja ja peptidejä
AT502275B1 (de) Immunantwort-induzierende zusammensetzungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17P Request for examination filed

Effective date: 20090630

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135403

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20130917

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/005 20060101ALI20130906BHEP

Ipc: C07H 21/02 20060101AFI20130906BHEP

17Q First examination report despatched

Effective date: 20160201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160614

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135403

Country of ref document: HK